In This Article:
Enzo Biochem (NYSE:ENZ) Third Quarter 2024 Results
Key Financial Results
-
Revenue: US$8.02m (down 50% from 3Q 2023).
-
Net loss: US$2.13m (loss narrowed by 86% from 3Q 2023).
-
US$0.042 loss per share (improved from US$0.31 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Enzo Biochem shares are up 2.7% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Enzo Biochem (1 is potentially serious) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com